OBJECTIVES: To explore HIV-infected patients' attitudes about buprenorphine treatment in office-based and opioid treatment program (OTP) settings. METHODS: We conducted in-depth qualitative interviews with 29 patients with co-existing HIV infection and opioid dependence seeking buprenorphine maintenance therapy in office-based and OTP settings. We used thematic analysis of transcribed audiorecorded interviews to identify themes. RESULTS: Patients voiced a strong preference for office-based treatment. Four themes emerged to explain this preference. First, patients perceived the greater convenience of office-based treatment as improving their ability to address HIV and other healthcare issues. Second, they perceived a strong patient-focused orientation in patient-provider relationships underpinning their preference for office-based care. This was manifest as increased trust, listening, empathy, and respect from office-based staff and providers. Third, they perceived shared power and responsibility in office-based settings. Finally, patients viewed office-based treatment as a more supportive environment for sobriety and relapse prevention. This was partly due to strong therapeutic alliances with office-based staff and providers who prioritized a harm reduction approach, but also due to the perception that the office-based settings were "safer" for sobriety, compared with increased opportunities for purchasing and using illicit opiates in OTP settings. CONCLUSIONS: HIV-infected patients with opioid dependence preferred office-based buprenorphine because they perceived it as offering a more patient-centered approach to care compared with OTP referral. Office-based buprenorphine may facilitate engagement in care for patients with co-existing opioid dependence and HIV infection.
OBJECTIVES: To explore HIV-infectedpatients' attitudes about buprenorphine treatment in office-based and opioid treatment program (OTP) settings. METHODS: We conducted in-depth qualitative interviews with 29 patients with co-existing HIV infection and opioid dependence seeking buprenorphine maintenance therapy in office-based and OTP settings. We used thematic analysis of transcribed audiorecorded interviews to identify themes. RESULTS:Patients voiced a strong preference for office-based treatment. Four themes emerged to explain this preference. First, patients perceived the greater convenience of office-based treatment as improving their ability to address HIV and other healthcare issues. Second, they perceived a strong patient-focused orientation in patient-provider relationships underpinning their preference for office-based care. This was manifest as increased trust, listening, empathy, and respect from office-based staff and providers. Third, they perceived shared power and responsibility in office-based settings. Finally, patients viewed office-based treatment as a more supportive environment for sobriety and relapse prevention. This was partly due to strong therapeutic alliances with office-based staff and providers who prioritized a harm reduction approach, but also due to the perception that the office-based settings were "safer" for sobriety, compared with increased opportunities for purchasing and using illicit opiates in OTP settings. CONCLUSIONS:HIV-infectedpatients with opioid dependence preferred office-based buprenorphine because they perceived it as offering a more patient-centered approach to care compared with OTP referral. Office-based buprenorphine may facilitate engagement in care for patients with co-existing opioid dependence and HIV infection.
Authors: Victor A Capoccia; Frances Cotter; David H Gustafson; Elaine F Cassidy; James H Ford; Lynn Madden; Betta H Owens; Scott O Farnum; Dennis McCarty; Todd Molfenter Journal: Jt Comm J Qual Patient Saf Date: 2007-02
Authors: David A Fiellin; Michael V Pantalon; Juliana P Pakes; Patrick G O'Connor; Marek Chawarski; Richard S Schottenfeld Journal: Am J Drug Alcohol Abuse Date: 2002 Impact factor: 3.829
Authors: Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Joseph O Merrill; Lorna A Rhodes; Richard A Deyo; G Alan Marlatt; Katharine A Bradley Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Andy Guise; Maureen Seguin; Gitau Mburu; Susie McLean; Pippa Grenfell; Zahed Islam; Sergii Filippovych; Happy Assan; Andrea Low; Peter Vickerman; Tim Rhodes Journal: AIDS Care Date: 2017-03-10
Authors: Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins Journal: Drug Alcohol Depend Date: 2011-07-08 Impact factor: 4.492
Authors: Aaron D Fox; Pooja A Shah; Nancy L Sohler; Carolina M Lopez; Joanna L Starrels; Chinazo O Cunningham Journal: Subst Abus Date: 2014 Impact factor: 3.716
Authors: Jan Gryczynski; Jerome H Jaffe; Robert P Schwartz; Kristi A Dušek; Nishan Gugsa; Cristin L Monroe; Kevin E O'Grady; Yngvild K Olsen; Shannon Gwin Mitchell Journal: Am J Addict Date: 2013 May-Jun
Authors: Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham Journal: J Opioid Manag Date: 2013 Mar-Apr